The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Ankylosing Spondylitis Drug-Global Market Insights and Sales Trends 2024
Synopsis
The global Ankylosing Spondylitis Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Ankylosing Spondylitis Drug in various end use industries. The expanding demands from the Hospitals and Clinics, are propelling Ankylosing Spondylitis Drug market. Cimzia, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Enbrel segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Ankylosing Spondylitis Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Ankylosing Spondylitis Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Ankylosing Spondylitis Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Ankylosing Spondylitis Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Ankylosing Spondylitis Drug covered in this report include Amgen, Wyeth, Takeda, Centocor, Schering-Plough, Mitsubishi Tanabe, Abbott, Eisai and Pfizer, etc.
The global Ankylosing Spondylitis Drug market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
Wyeth
Takeda
Centocor
Schering-Plough
Mitsubishi Tanabe
Abbott
Eisai
Pfizer
Johnson & Johnson
Global Ankylosing Spondylitis Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Ankylosing Spondylitis Drug market, Segment by Type:
Cimzia
Enbrel
Humira
Remicade
Simponi
Others
Global Ankylosing Spondylitis Drug market, by Application
Hospitals
Clinics
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Ankylosing Spondylitis Drug companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Ankylosing Spondylitis Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Ankylosing Spondylitis Drug in various end use industries. The expanding demands from the Hospitals and Clinics, are propelling Ankylosing Spondylitis Drug market. Cimzia, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Enbrel segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Ankylosing Spondylitis Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Ankylosing Spondylitis Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Ankylosing Spondylitis Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Ankylosing Spondylitis Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Ankylosing Spondylitis Drug covered in this report include Amgen, Wyeth, Takeda, Centocor, Schering-Plough, Mitsubishi Tanabe, Abbott, Eisai and Pfizer, etc.
The global Ankylosing Spondylitis Drug market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
Wyeth
Takeda
Centocor
Schering-Plough
Mitsubishi Tanabe
Abbott
Eisai
Pfizer
Johnson & Johnson
Global Ankylosing Spondylitis Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Ankylosing Spondylitis Drug market, Segment by Type:
Cimzia
Enbrel
Humira
Remicade
Simponi
Others
Global Ankylosing Spondylitis Drug market, by Application
Hospitals
Clinics
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Ankylosing Spondylitis Drug companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Ankylosing Spondylitis Drug
1.1 Ankylosing Spondylitis Drug Market Overview
1.1.1 Ankylosing Spondylitis Drug Product Scope
1.1.2 Ankylosing Spondylitis Drug Market Status and Outlook
1.2 Global Ankylosing Spondylitis Drug Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Ankylosing Spondylitis Drug Market Size by Region (2018-2029)
1.4 Global Ankylosing Spondylitis Drug Historic Market Size by Region (2018-2023)
1.5 Global Ankylosing Spondylitis Drug Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Ankylosing Spondylitis Drug Market Size (2018-2029)
1.6.1 North America Ankylosing Spondylitis Drug Market Size (2018-2029)
1.6.2 Europe Ankylosing Spondylitis Drug Market Size (2018-2029)
1.6.3 Asia-Pacific Ankylosing Spondylitis Drug Market Size (2018-2029)
1.6.4 Latin America Ankylosing Spondylitis Drug Market Size (2018-2029)
1.6.5 Middle East & Africa Ankylosing Spondylitis Drug Market Size (2018-2029)
2 Ankylosing Spondylitis Drug Market by Type
2.1 Introduction
2.1.1 Cimzia
2.1.2 Enbrel
2.1.3 Humira
2.1.4 Remicade
2.1.5 Simponi
2.1.6 Others
2.2 Global Ankylosing Spondylitis Drug Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Ankylosing Spondylitis Drug Historic Market Size by Type (2018-2023)
2.2.2 Global Ankylosing Spondylitis Drug Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Ankylosing Spondylitis Drug Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Ankylosing Spondylitis Drug Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Ankylosing Spondylitis Drug Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Ankylosing Spondylitis Drug Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Ankylosing Spondylitis Drug Revenue Breakdown by Type (2018-2029)
3 Ankylosing Spondylitis Drug Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.2 Global Ankylosing Spondylitis Drug Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Ankylosing Spondylitis Drug Historic Market Size by Application (2018-2023)
3.2.2 Global Ankylosing Spondylitis Drug Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Ankylosing Spondylitis Drug Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Ankylosing Spondylitis Drug Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Ankylosing Spondylitis Drug Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Ankylosing Spondylitis Drug Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Ankylosing Spondylitis Drug Revenue Breakdown by Application (2018-2029)
4 Ankylosing Spondylitis Drug Competition Analysis by Players
4.1 Global Ankylosing Spondylitis Drug Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Ankylosing Spondylitis Drug as of 2022)
4.3 Date of Key Players Enter into Ankylosing Spondylitis Drug Market
4.4 Global Top Players Ankylosing Spondylitis Drug Headquarters and Area Served
4.5 Key Players Ankylosing Spondylitis Drug Product Solution and Service
4.6 Competitive Status
4.6.1 Ankylosing Spondylitis Drug Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Amgen
5.1.1 Amgen Profile
5.1.2 Amgen Main Business
5.1.3 Amgen Ankylosing Spondylitis Drug Products, Services and Solutions
5.1.4 Amgen Ankylosing Spondylitis Drug Revenue (US$ Million) & (2018-2023)
5.1.5 Amgen Recent Developments
5.2 Wyeth
5.2.1 Wyeth Profile
5.2.2 Wyeth Main Business
5.2.3 Wyeth Ankylosing Spondylitis Drug Products, Services and Solutions
5.2.4 Wyeth Ankylosing Spondylitis Drug Revenue (US$ Million) & (2018-2023)
5.2.5 Wyeth Recent Developments
5.3 Takeda
5.3.1 Takeda Profile
5.3.2 Takeda Main Business
5.3.3 Takeda Ankylosing Spondylitis Drug Products, Services and Solutions
5.3.4 Takeda Ankylosing Spondylitis Drug Revenue (US$ Million) & (2018-2023)
5.3.5 Centocor Recent Developments
5.4 Centocor
5.4.1 Centocor Profile
5.4.2 Centocor Main Business
5.4.3 Centocor Ankylosing Spondylitis Drug Products, Services and Solutions
5.4.4 Centocor Ankylosing Spondylitis Drug Revenue (US$ Million) & (2018-2023)
5.4.5 Centocor Recent Developments
5.5 Schering-Plough
5.5.1 Schering-Plough Profile
5.5.2 Schering-Plough Main Business
5.5.3 Schering-Plough Ankylosing Spondylitis Drug Products, Services and Solutions
5.5.4 Schering-Plough Ankylosing Spondylitis Drug Revenue (US$ Million) & (2018-2023)
5.5.5 Schering-Plough Recent Developments
5.6 Mitsubishi Tanabe
5.6.1 Mitsubishi Tanabe Profile
5.6.2 Mitsubishi Tanabe Main Business
5.6.3 Mitsubishi Tanabe Ankylosing Spondylitis Drug Products, Services and Solutions
5.6.4 Mitsubishi Tanabe Ankylosing Spondylitis Drug Revenue (US$ Million) & (2018-2023)
5.6.5 Mitsubishi Tanabe Recent Developments
5.7 Abbott
5.7.1 Abbott Profile
5.7.2 Abbott Main Business
5.7.3 Abbott Ankylosing Spondylitis Drug Products, Services and Solutions
5.7.4 Abbott Ankylosing Spondylitis Drug Revenue (US$ Million) & (2018-2023)
5.7.5 Abbott Recent Developments
5.8 Eisai
5.8.1 Eisai Profile
5.8.2 Eisai Main Business
5.8.3 Eisai Ankylosing Spondylitis Drug Products, Services and Solutions
5.8.4 Eisai Ankylosing Spondylitis Drug Revenue (US$ Million) & (2018-2023)
5.8.5 Eisai Recent Developments
5.9 Pfizer
5.9.1 Pfizer Profile
5.9.2 Pfizer Main Business
5.9.3 Pfizer Ankylosing Spondylitis Drug Products, Services and Solutions
5.9.4 Pfizer Ankylosing Spondylitis Drug Revenue (US$ Million) & (2018-2023)
5.9.5 Pfizer Recent Developments
5.10 Johnson & Johnson
5.10.1 Johnson & Johnson Profile
5.10.2 Johnson & Johnson Main Business
5.10.3 Johnson & Johnson Ankylosing Spondylitis Drug Products, Services and Solutions
5.10.4 Johnson & Johnson Ankylosing Spondylitis Drug Revenue (US$ Million) & (2018-2023)
5.10.5 Johnson & Johnson Recent Developments
6 North America
6.1 North America Ankylosing Spondylitis Drug Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Ankylosing Spondylitis Drug Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Ankylosing Spondylitis Drug Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Ankylosing Spondylitis Drug Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Ankylosing Spondylitis Drug Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Ankylosing Spondylitis Drug Market Dynamics
11.1 Ankylosing Spondylitis Drug Industry Trends
11.2 Ankylosing Spondylitis Drug Market Drivers
11.3 Ankylosing Spondylitis Drug Market Challenges
11.4 Ankylosing Spondylitis Drug Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
